IM/SC Childn 1-5 yr Single dose of 0.5 mL, 6-12 mth 2 doses of 0.5 mL administered 1 mth apart, followed by a booster inj (0.5 mL) at 18 mth of age, <6 mth 3 successive doses of 0.5 mL administered 1 or 2 mth apart, followed by a booster inj (0.5 mL) 1 yr after the 3rd inj.
Hypersensitivity to any of the vaccine components, to tetanus protein, to formaldehyde, or following prior inj of a HIB conjugate vaccine. Postpone vaccination in the presence of fever or acute illness.
Do not inj intravascularly. Immunodeficiency or immunosuppressive treatment (corticosteroids, cytotoxic drugs, RT) may reduce immune response to the vaccine. Risk of bleeding during IM administration in patients w/ bleeding (eg, thrombocytopenia) or clotting disorders. A +ve urine test for HIB capsular polysaccharide antigen can be observed w/in 1-2 wk following vaccination. Administer at 2 separate inj sites during concomitant use w/ other vaccines. Pregnancy & lactation.
Sign Out
